Novo A/S partner joins Cytochroma board of directors
This article was originally published in Scrip
Executive Summary
Cytochroma, a clinical-stage speciality pharmaceutical company, has appointed Dr Peter Moldt to its board of directors. He is a partner in Novo A/S, part of the Novo Nordisk Foundation, which he joined in 2009. Before that, Dr Moldt served as CEO of Curalogic, a development-stage biopharmaceutical company, and as chief operating officer of 7TM Pharma, a drug discovery company, both of which he co-founded. Dr Moldt has also worked with NeuroSearch, where he specialised in preclinical and clinical drug development. Dr Moldt will replace Ulrik Spork, who joined Cytochroma's board in 2008, also representing Novo A/S.